Actively Recruiting
Optimized and Personalized Trans-cranial Brain Stimulation in Partial Refractory Epilepsies
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2024-01-31
20
Participants Needed
1
Research Sites
161 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Epilepsy is one of the most common neurological diseases, affecting between 0.5% and 1% of the general population. Therefore, new diagnostic and treatment methods are having a big impact on society. Epilepsy is also one of the most commonly diagnosed pediatric neurological disorders, with long-term implications for the quality of life of those affected and their relatives. In only two-thirds of cases, seizures can be adequately controlled with anticonvulsant drug therapy. For other patients with a drug-resistant focal epilepsy (up to around 2 million in Europe) epilepsy surgery is currently the most effective treatment. However, only 15-20% of these drug-resistant patients are eligible for epilepsy surgery. This is either because the cortical epileptogenic zone cannot be localized with sufficient precision with standard diagnostic means, or because the epileptogenic zone overlaps meaningful cortical areas, so that it cannot be surgically removed without considerable neurological deficit.
CONDITIONS
Official Title
Optimized and Personalized Trans-cranial Brain Stimulation in Partial Refractory Epilepsies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 1 to 18 years with refractory partial epilepsy considered potentially surgical
- Failure of adequate trials of two antiepileptic drugs with ongoing seizures
- Presence of interictal epileptic spikes on EEG or magnetoencephalography
- Undergoing structural MRI
- Agreement to participate in the PerEpi 1 study for optimization of epileptic source location and stimulation parameters
- At least 4 seizures per month
You will not qualify if you...
- Not meeting the age criteria of 1 to 18 years
- Having generalized epilepsy
- Having diffuse interictal peaks or serious general health and vital function impairment
- Refusal by patient or parent
- Pregnant, parturient, or breastfeeding women
- Contraindications to use of mc-tDCS stimulation without seizure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Amiens
Amiens, France, 80054
Actively Recruiting
Research Team
F
Fabrice Wallois, Pr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here